SUNPHARMA share price target 2026

Price target: support and resistanceComputed 30 Jun 2026

Support and resistance for SUNPHARMA are read inside the latest show; no spot was printed in the most recent editorial note.

Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 9 Jun 2026.

These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the SUNPHARMA chart, refreshed every end-of-day run.

The Crack Score, and how it is built41 / 100 · Range / mixed

The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for SUNPHARMA, so the figure is a transparent signal rather than a vibe.

Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.

About Sun Pharmaceutical Industries LimitedBusiness profile

What SUNPHARMA actually does, and the edge that holds its position.

Sun Pharma is trying to graduate from a price-taking generics giant into a margin-rich specialty player, and that mix shift is the real story under the headline of being India's largest drugmaker. It spans US generics, branded specialty drugs in dermatology and ophthalmology, India branded generics, and emerging-market formulations. Specialty brands like Ilumya for psoriasis give it a differentiated US position beyond commodity generics, which is exactly the higher-value pivot the market is paying up for.

Sun Pharma's moat is its manufacturing scale and USFDA-compliant facility network, combined with a specialty-drug pipeline in the US that generates higher margins than the commoditised generics pool. The India branded-generic business benefits from deep doctor relationships and a field-force built over decades, making brand switching slow.

The F&O viewHorizon · swing

How the futures and options structure on SUNPHARMA reads right now.

The futures and options read on SUNPHARMA leans to a two-way / range write. Strike-level positioning is read inside the latest show, against the printed spot. Single-stock F&O on SUNPHARMA is thinner than the index, so open-interest shifts read with more noise; the desk weights price structure over raw OI. This is a structural reading of positioning, not a derivatives trade recommendation.

Why it movedLatest editorial line

The most recent BazaarBaazi read on what is driving SUNPHARMA.

Systematic read: a disclosed, data-only model on real 1-year price structure.

Read in Systematic Read on 9 Jun 2026. Why SUNPHARMA moved, the living explainer, tracks every move on one URL.

The 2026 to 2030 pictureStructural read

What genuinely drives SUNPHARMA over a multi-year horizon. A structural read, not a price forecast.

Over 2026 to 2030, the primary growth drivers for Sun Pharma are specialty-drug launches in the US and Europe expanding the portfolio beyond Ilumya, India branded-generic business compounding as healthcare access grows, and emerging-market formulation revenues scaling. The key risk is USFDA inspection observations at any key manufacturing facility or generic pricing erosion accelerating in the US base business. What BazaarBaazi thinks: the specialty pivot is the right move and the India branded book is genuinely sticky, but the risk no score can pre-empt is a single USFDA inspection, one import alert on a key plant can erase a chunk of US revenue overnight in a way no technical setup will see coming.

What to watch:

• US specialty revenue growth and new specialty-drug approval timelines
• USFDA inspection outcomes for key manufacturing facilities
• India branded-generic business revenue growth and new therapeutic launches
• Gross margin expansion as specialty mix rises within the US portfolio
• Emerging-market formulation revenue as a diversification gauge

Peers and how to compare5 listed names

The listed names SUNPHARMA is most often read against. Compare them on the same Crack Score and levels.

Live valuation readQ4 FY26 earnings · live spot

P/E, P/B, yield and the quality set for Sun Pharmaceutical Industries Limited, computed from the latest filed results times the live spot. The price-driven ratios (marked) refresh every session; ROE and margins hold until the next results.

Stored from Sun Pharmaceutical Industries Limited's filed results, as of 2026-06-30 and currency-checked. Price input Rs 1,862.50 from baked EOD spot. Open the calculator, move the price and watch every ratio react.

Latest filed resultsQ4 FY26

Sun Pharmaceutical Industries Limited's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.

See every Q4 result the desk has read.

Earnings historyLast 8 quarters

Sun Pharmaceutical Industries Limited's official quarterly revenue, EPS and Result Pulse trail from the verified filings export. These are quarterly facts, not TTM valuation inputs.

What changed53 disclosures

Every recent official filing from Sun Pharmaceutical Industries Limited, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.

See what changed across the whole market.

Key fundamentalsEditorial reference

The anchor data BazaarBaazi references when reading the SUNPHARMA chart. Not a substitute for a registered research note.

Reference chartLevels in show

The daily frame the desk reads on SUNPHARMA.

FAQ15 reader questions · AEO-eligible

The line on SUNPHARMA, distilled and schema-marked for AI Overview, Perplexity, and reader search.

Related stock views

The names BazaarBaazi reads alongside SUNPHARMA, each a living view refreshed every end-of-day run.